<DOC>
	<DOCNO>NCT00005089</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Monoclonal antibody , rituximab , locate cancer cell either kill deliver cancer-killing substance without harm normal cell . Radiation therapy use high-energy x-rays damage cancer cell . Combining chemotherapy monoclonal antibody therapy radiation therapy may kill cancer cell . PURPOSE : Phase II trial study effectiveness combination chemotherapy plus rituximab radiation therapy treat patient stage I stage II non-Hodgkin 's lymphoma .</brief_summary>
	<brief_title>S0014 Combination Chemotherapy Plus Rituximab Radiation Therapy Treating Patients With Stage I Stage II Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : I. Assess two year progression free survival treatment cyclophosphamide , doxorubicin , vincristine , prednisone ( CHOP ) plus rituximab follow radiotherapy patient stage I , IE , non-bulky stage II IIE high risk localize intermediate high grade non-Hodgkin 's lymphoma . II . Determine toxicity treatment patient . OUTLINE : Patients receive rituximab IV day 1 8 first course , day 1 course 2 3 . Patients receive cyclophosphamide IV 1-2 hour , doxorubicin IV , vincristine IV day 10 first course , day 3 course 2 3 . Patients receive oral prednisone day 10-14 first course , day 3-7 course 2 3 . Treatment repeat every 21 day 3 course absence disease progression unacceptable toxicity . Chemotherapy follow radiotherapy administer 5 day week 4-5 week . Patients follow every 6 month two year , annually thereafter . PROJECTED ACCRUAL : A total 60 patient accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm stage I , IE , nonbulky II IIE nonHodgkin 's lymphoma one follow subtypes : Diffuse large Bcell Mantle cell High grade Bcell , Burkitt 's Burkitt like Anaplastic large cell ( Bcell phenotype ) Lymphoma must express CD20 All disease must encompassable single radiation port ( include resect disease ) Must least 1 follow adverse prognostic feature : Nonbulky stage II nonbulky stage IIE disease Over 60 year age Zubrod performance status 2 Elevated serum LDH A new classification scheme adult nonHodgkin 's lymphoma adopt PDQ . The terminology `` indolent '' `` aggressive '' lymphoma replace former terminology `` low '' , `` intermediate '' , `` high '' grade lymphoma . However , protocol us former terminology . PATIENT CHARACTERISTICS : Age : Over 18 Performance status : Zubrod 02 Life expectancy : Not specify Hematopoietic : Not specify Hepatic : Not specify Renal : Not specify Other : No medical contraindication CHOP chemotherapy rituximab No prior malignancy within past 5 year except adequately treat basal cell squamous cell skin cancer carcinoma situ cervix No AIDS HIV Not pregnant nursing Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : No prior monoclonal antibody therapy Chemotherapy : No prior chemotherapy lymphoma Endocrine therapy : Not specify Radiotherapy : No prior radiotherapy lymphoma Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>stage I adult diffuse large cell lymphoma</keyword>
	<keyword>stage I adult Burkitt lymphoma</keyword>
	<keyword>stage I mantle cell lymphoma</keyword>
	<keyword>contiguous stage II mantle cell lymphoma</keyword>
	<keyword>contiguous stage II adult diffuse large cell lymphoma</keyword>
	<keyword>contiguous stage II adult Burkitt lymphoma</keyword>
	<keyword>noncontiguous stage II mantle cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse large cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult Burkitt lymphoma</keyword>
</DOC>